logo
logo

Colossal Biosciences raised more than $225 million in funding to pursue de-extinction of prehistoric creatures and conservation efforts.

Apr 12, 2024•over 1 year ago

Amount Raised

$225 Million

AustinBiotechnology

Investors

At One VenturesBob NelsenBreyer CapitalBold Capital PartnersUsit

Description

Colossal Biosciences has raised more than $225 million to date, with backers including USIT, Bold Capital Partners, Breyer Capital, Bob Nelsen, At One Ventures, and more. The company continues to pursue the de-extinction of the woolly mammoth, the Tasmanian tiger, and the dodo, alongside extensive conservation efforts.

Company Information

Company

Colossal Biosciences

Location

Austin, Texas, United States

About

Colossal was founded by emerging technology and software entrepreneur Ben Lamm and world-renowned geneticist and serial biotech entrepreneur George Church, Ph.D., and is the first to apply CRISPR technology for the purposes of species de-extinction. Colossal creates innovative technologies for species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. Colossal is accepting humanity's duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People